| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | 2B218X5QIY |
| InChI Key | OCKIPDMKGPYYJS-ZDUSSCGKSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C13H16N2O |
| Molecular Weight | 216.28 |
| AlogP | 1.48 |
| Hydrogen Bond Acceptor | 3.0 |
| Hydrogen Bond Donor | 0.0 |
| Number of Rotational Bond | 0.0 |
| Polar Surface Area | 25.36 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 1.0 |
| Heavy Atoms | 16.0 |
| Primary Target | |
|---|---|
| nicotinic acetylcholine receptor α7 subunit |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Ion channel
Ligand-gated ion channel
5HT3 receptor
|
- | - | - | 12 | - | |
|
Ion channel
Ligand-gated ion channel
Nicotinic acetylcholine receptor
Nicotinic acetylcholine receptor alpha subunit
|
340 | - | - | 3-3 | - | |
|
Ion channel
Ligand-gated ion channel
Nicotinic acetylcholine receptor
Nicotinic acetylcholine receptor beta subunit
|
- | - | - | 140 | - |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Schizophrenia | 2 | D012559 | ClinicalTrials |
| Alzheimer Disease | 1 | D000544 | ClinicalTrials |
| Resources | Reference |
|---|---|
| ChEMBL | CHEMBL2151437 |
| DrugBank | DB12145 |
| FDA SRS | 2B218X5QIY |
| Guide to Pharmacology | 7697 |
| SureChEMBL | SCHEMBL1459640 |
| ZINC | ZINC000033961869 |